Eli Lilly's weight loss injection: what you're actually deciding

Is this the right injection for your situation?

The decision to start any weight-loss injection is a clinical one, but it helps to understand the landscape before your consultation. Mounjaro sits in a category of medicines called GLP-1 receptor agonists, but it goes a step further by also activating GIP receptors. That dual action is why clinical trial results have, on average, exceeded those seen with single-pathway injections. In the SURMOUNT-5 head-to-head trial published in the New England Journal of Medicine (2025), tirzepatide produced greater average weight reduction than semaglutide 2.4 mg over 72 weeks, a direct comparison that NICE also noted in its assessment.

Whether that difference is the decisive factor for you depends on your health picture. A prescriber will look at your BMI, any existing conditions such as type 2 diabetes, hypertension or sleep apnoea, your medication list, and your history. Mounjaro is also licensed for type 2 diabetes, which sometimes makes it the preferred choice when both conditions are present. If you want a broader sense of what licensed weight-loss injections currently exist in the UK, the overview of weight-loss injections is a useful starting point.

One practical note: the pen itself is a pre-filled KwikPen containing four weekly doses. Nothing needs drawing up or mixing. Each week you select a new injection site on your abdomen, thigh or upper arm, rotate to avoid using the same spot repeatedly, and administer the dose. If you are weighing up which weight loss injection is right for you before speaking to a prescriber, it is worth familiarising yourself with how the different options compare. The guide to abdominal injection technique covers the mechanics in more detail for anyone who finds the idea daunting.

What the dose ladder looks like, and why the first pen isn't the full story

The starting dose of 2.5 mg exists to help your system adjust, not to produce immediate large-scale weight loss. Nausea, the most commonly reported side effect, is far more manageable when the dose climbs gradually. A prescriber then titrates upward in roughly four-week steps, though the pace depends on how you tolerate each level. Most people reach a maintenance dose somewhere between 5 mg and 15 mg.

The cost context for weight-loss injections is worth reading before starting, because pricing varies significantly by dose and by provider. Eli Lilly raised Mounjaro's UK list price from 1 September 2025, with the highest dose's list price rising from around £122 to around £330 per four-week pen; typical private prices since then range roughly £149–£375 per month depending on dose and where you source it.

At a registered service like a regulated pharmacy offering Lilly's tirzepatide, pricing covers the full clinical process: consultation, prescription, the medicine, and delivery. It is worth checking what any quoted price actually includes before comparing figures across providers. A number that looks lower sometimes excludes clinical review, and for a Prescription-Only Medicine that omission matters.

Side effects to know about before you commit

The most common side effects of Mounjaro are gastrointestinal: nausea, loose stools, constipation, acid reflux, burping and, less often, vomiting. Most people find these are worst in the first few weeks after starting or after a dose increase, and they tend to settle. Eating smaller portions and avoiding fatty or very rich food in the early weeks makes a meaningful difference for most people.

A smaller number of patients experience fatigue, headache or dizziness, particularly early on. More serious but infrequent reactions include pancreatitis: in January 2026 the MHRA issued a Drug Safety Update on GLP-1 medicines specifically highlighting acute pancreatitis as a known risk. The symptom to act on immediately is severe, persistent stomach pain that spreads to the back, with or without vomiting. That warrants same-day medical attention, not a wait-and-see approach.

Contraception is worth raising explicitly with a prescriber if you take the oral contraceptive pill. For tirzepatide specifically, the slowing of gastric emptying in the early weeks of treatment and after each dose increase can reduce pill absorption; adding a barrier method for the four weeks following each dose step is the standard advice. Full safety information is set out on the safety of weight-loss injections page, and the NHS tirzepatide medicines page gives a thorough patient-level overview.

NHS access versus starting privately

NICE recommended tirzepatide for NHS use in December 2024 (TA1026), but the rollout is phased and the thresholds are strict. Currently, NHS access requires a BMI of 40 or above alongside four or more qualifying conditions from a defined list that includes type 2 diabetes, high blood pressure, dyslipidaemia, obstructive sleep apnoea and cardiovascular disease. The next cohort (BMI 35–39.9 with four or more conditions) became eligible in June 2026. Many people who would benefit clinically don't yet qualify under the NHS criteria, or do qualify but face long waiting lists. A regulated private pharmacy is the legal alternative for those who want to start sooner, provided a prescriber assesses them first.

At nume (sorry, at our GPhC-registered pharmacy) a named prescriber reads every consultation the same day; no automated filtering, no algorithm making the clinical call. If approved, treatment is dispatched before close of business and arrives the next working day via DPD. The box that lands on your doorstep is plain and unbranded, with a tracking number on your phone the moment it leaves us. Our clinical team's approach is described on the clinical team page if you want to understand who is making that review. To see whether Eli Lilly's weight loss injection is clinically suitable for you, the right next step is a free consultation rather than a purchase decision.